Quarterly report pursuant to Section 13 or 15(d)

Accrued Expenses

v3.24.1.1.u2
Accrued Expenses
3 Months Ended
Mar. 31, 2024
Payables and Accruals [Abstract]  
Accrued Expenses

8. Accrued Expenses

Accrued expenses consisted of the following as of March 31, 2024 and December 31, 2023 (in thousands):

 

 

March 31, 2024

 

 

December 31, 2023

 

External research and preclinical development

 

$

8,220

 

 

$

8,001

 

Employee compensation and benefits

 

 

2,487

 

 

 

6,993

 

Professional fees

 

 

1,022

 

 

 

1,015

 

Facilities and other

 

 

152

 

 

 

137

 

Accrued expenses

 

$

11,881

 

 

$

16,146